Literature DB >> 11488772

Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP).

I B Wilkinson1, C M McEniery, K H Bongaerts, H MacCallum, D J Webb, J R Cockcroft.   

Abstract

AIMS: To compare the haemodynamic responses of proadrenomedullin N-terminal 20 peptide (PAMP) and adrenomedullin (ADM) in the forearm vascular bed of healthy male volunteers, and to investigate the role of neutral endopeptidase (NEP) in the metabolism of ADM.
METHODS: On two separate occasions, ADM (1-30 pmol x min(-1)) and PAMP (100-3000 pmol x min(-1)) were infused into the brachial artery of eight male subjects, and forearm blood flow (FBF) assessed using venous occlusion plethysmography. In a second study, eight male subjects received the same doses of ADM, co-infused with either the NEP inhibitor thiorphan (30 nmol x min(-1)) or the control vasoconstrictor noradrenaline (120 pmol x min(-1)), on separate occasions. Both studies were conducted in a double-blind, randomized manner.
RESULTS: ADM and PAMP produced a dose-dependent increase in FBF (P < or = 0.002). Based on the dose producing a 50% increase in FBF, ADM was approximately 60 times more potent than PAMP. Thiorphan and noradrenaline produced similar reductions in FBF of 14 +/- 4% (mean +/- s.e. mean) and 22 +/- 6%, respectively (P = 0.4). However, the area under the dose-response curve was significantly greater during co-infusion of ADM with thiorphan than with noradrenaline (P = 0.028), as was the maximum increase in FBF ratio (2.1 +/- 1.0 vs 1.2 +/- 0.2; P = 0.030).
CONCLUSIONS: ADM and PAMP both produce a local dose-related vasodilatation in the human forearm, but PAMP is approximately 60 times less potent than ADM. In addition, NEP inhibition potentiates the haemodynamic effects of ADM. These findings suggest that PAMP may not play a role in the physiological regulation of blood flow. However, in pathophysiological conditions such as hypertension and heart failure, NEP inhibition may exert a beneficial effect by increasing the biological activity of ADM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488772      PMCID: PMC2014526          DOI: 10.1046/j.0306-5251.2001.1420.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  39 in total

Review 1.  Adrenomedullin.

Authors:  A M Richards; M G Nicholls; L Lewis; J G Lainchbury
Journal:  Clin Sci (Lond)       Date:  1996-07       Impact factor: 6.124

2.  Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.

Authors:  N Benjamin; J R Cockcroft; J G Collier; C T Dollery; J M Ritter; D J Webb
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

3.  Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme.

Authors:  J G Collier; B F Robinson; J R Vane
Journal:  Lancet       Date:  1973-01-13       Impact factor: 79.321

4.  Elevation of circulating proadrenomedullin-N terminal 20-peptide in thyrotoxicosis.

Authors:  M Taniyama; K Kitamura; Y Ban; E Sugita; K Ito; T Katagiri
Journal:  Clin Endocrinol (Oxf)       Date:  1997-03       Impact factor: 3.478

5.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Authors:  J L Rouleau; M A Pfeffer; D J Stewart; D Isaac; F Sestier; E K Kerut; C B Porter; G Proulx; C Qian; A J Block
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

6.  Proadrenomedullin N-terminal 20 peptide is rapidly cleaved by neutral endopeptidase.

Authors:  Y Nagatomo; K Kitamura; K Kangawa; Y Fujimoto; T Eto
Journal:  Biochem Biophys Res Commun       Date:  1996-06-25       Impact factor: 3.575

7.  Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm.

Authors:  K P O'Kane; D J Webb; J G Collier; P J Vallance
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

8.  Endothelin is a potent long-lasting vasoconstrictor in men.

Authors:  J G Clarke; N Benjamin; S W Larkin; D J Webb; G J Davies; A Maseri
Journal:  Am J Physiol       Date:  1989-12

9.  Contribution of endogenous generation of endothelin-1 to basal vascular tone.

Authors:  W G Haynes; D J Webb
Journal:  Lancet       Date:  1994-09-24       Impact factor: 79.321

10.  Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.

Authors:  C J Ferro; J C Spratt; W G Haynes; D J Webb
Journal:  Circulation       Date:  1998-06-16       Impact factor: 29.690

View more
  13 in total

1.  Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target.

Authors:  X Fan; J Xie; J Tian
Journal:  Cardiovasc Pharm Open Access       Date:  2017-01-31

Review 2.  Sacubitril/valsartan in heart failure: latest evidence and place in therapy.

Authors:  Edgardo Kaplinsky
Journal:  Ther Adv Chronic Dis       Date:  2016-10-19       Impact factor: 5.091

Review 3.  Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure.

Authors:  Barry Greenberg
Journal:  Int J Heart Fail       Date:  2020-03-24

4.  Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

5.  Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator.

Authors:  Alfredo Martínez; Hae-Ryong Oh; Edward J Unsworth; Claudia Bregonzio; Juan M Saavedra; William G Stetler-Stevenson; Frank Cuttitta
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

Review 6.  Chronic heart failure: a disease of the brain.

Authors:  Ram B Singh; Krasimira Hristova; Jan Fedacko; Galal El-Kilany; Germaine Cornelissen
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

7.  The expression and regulation of adrenomedullin in the human endometrium: a candidate for endometrial repair.

Authors:  Jacqueline A Maybin; Sharon Battersby; Nikhil Hirani; Leonid L Nikitenko; Hilary O D Critchley; Henry N Jabbour
Journal:  Endocrinology       Date:  2011-05-10       Impact factor: 4.736

8.  Use of sacubitril/valsartan in acute decompensated heart failure: a case report.

Authors:  Taison D Bell; Adrien J Mazer; P Elliott Miller; Jeffrey R Strich; Vandana Sachdev; Mary E Wright; Michael A Solomon
Journal:  ESC Heart Fail       Date:  2017-10-16

9.  Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.

Authors:  Domingo Pascual-Figal; Rolf Wachter; Michele Senni; Jan Belohlavek; Adele Noè; David Carr; Dmytro Butylin
Journal:  ESC Heart Fail       Date:  2017-12-14

10.  Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction.

Authors:  Damien Legallois; Clémence Macquaire; Amir Hodzic; Stéphane Allouche; Ismaïl El Khouakhi; Alain Manrique; Paul Milliez; Eric Saloux; Farzin Beygui
Journal:  BMC Cardiovasc Disord       Date:  2020-07-02       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.